Compare Sanofi SA (SNY) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.68. The key difference: Sanofi SA pays a 5.5% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and Sanofi SA is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| SNY | YMAG | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $52.34 | $15.98 |
52-Week Low | $41.33 | $11.00 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YMAG trades at $11.63, up 0.17% with a neutral technical signal. The ETF provides weekly dividend distributions, recently ranging from $0.07 to $0.40 per share. Key financial ratios are unavailable, but the fund's strategy focuses on option income from Magnificent Seven stocks. Recent news highlights consistent distribution announcements and tactical performance discussions.
Outlook hinges on option income strategy effectiveness in volatile markets. Opportunities include high yield potential, but risks involve NAV decay and expense ratio drag. Investor sentiment is mixed, with some analysts citing underperformance versus benchmarks amid low implied volatility reducing yield potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
